Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 14/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.48 |
| ▸ | ILK | Q13418 | 2/20 | 0.46 |
| ▸ | AKR1A1 | P14550 | 4/20 | 0.46 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.45 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | SCN4A | P35499 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15882028 | 0.86 | TRPV1 (0.40) | DYRK1AAKR1B1TRPV1ILKAKR1A1 | |
| SCHEMBL359623 | 0.84 | DYRK1A (0.49) | DYRK1AAKR1B1TRPV1ILKAKR1A1 | |
| SCHEMBL7082892 | 0.84 | DYRK1A (0.49) | DYRK1AAKR1B1TRPV1ILKAKR1A1 | |
| SCHEMBL3265720 | 0.84 | LOXL2 (0.59) | DYRK1AAKR1B1TRPV1ILKAKR1A1 | |
| SCHEMBL17484182 | 0.84 | NPC1 (0.58) | DYRK1AAKR1B1TRPV1ILKAKR1A1 | |
| Hydrochloric Acid SCHEMBL30209135 | 0.83 | LOXL2 (0.58) | DYRK1AAKR1B1TRPV1ILKAKR1A1 | |
| Hydrochloric Acid SCHEMBL15708092 | 0.83 | DYRK1A (0.48) | DYRK1AAKR1B1TRPV1ILKAKR1A1 | |
| SCHEMBL4900594 | 0.81 | ILK (0.47) | DYRK1AAKR1B1TRPV1ILKAKR1A1 | |
| SCHEMBL20254213 | 0.81 | DYRK1A (0.50) | DYRK1AAKR1B1TRPV1ILKAKR1A1 | |
| SCHEMBL5632209 | 0.81 | DYRK1A (0.50) | DYRK1AAKR1B1TRPV1ILKAKR1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180907-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2024-06-06 | — | — | US | disclosed |
| US-11730737-B2 | Aldose reductase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730737-B2 | Aldose reductase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730737-B2 | Aldose reductase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-22 | — | — | US | disclosed |
| EP-4124620-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2023-02-01 | — | — | EP | disclosed |
| EP-4124620-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2023-02-01 | — | — | EP | disclosed |
| US-11529349-B2 | Aldose reductase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-12-20 | — | — | US | disclosed |
| US-11529349-B2 | Aldose reductase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-12-20 | — | — | US | disclosed |
| EP-3597650-B1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | UNIV COLUMBIA (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20200289512-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2020-09-17 | — | — | US | disclosed |
| US-8916563-B2 | Aldose reductase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916563-B2 | Aldose reductase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916563-B2 | Aldose reductase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-12-23 | — | — | US | disclosed |
| WO-2014113380-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-07-24 | — | — | WO | disclosed |
| US-20130225592-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-08-29 | — | — | US | disclosed |
| US-20130225592-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-08-29 | — | — | US | disclosed |
| US-20130225592-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-08-29 | — | — | US | disclosed |
| EP-2593456-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012009553-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012009553-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180907-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | ALDOA, AKR1B1, AKR1C2 | DYRK1A 3857/4885AKR1B1 2/4885TRPV1 3283/4885 |
| US-20200289512-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | ALDOA, AKR1B1, AKR1C2 | DYRK1A 3857/4885AKR1B1 2/4885TRPV1 3283/4885 |
| US-11529349-B2 | Aldose reductase inhibitors and uses thereof | ALDOA, AKR1B1, AKR1C2 | DYRK1A 3857/4885AKR1B1 2/4885TRPV1 3283/4885 |
| US-20130225592-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | ALDOA, AKR1B1, AKR1C2 | DYRK1A 3857/4885AKR1B1 2/4885TRPV1 3283/4885 |
| US-11730737-B2 | Aldose reductase inhibitors and uses thereof | ALDOA, AKR1B1, AKR1C2 | DYRK1A 3857/4885AKR1B1 2/4885TRPV1 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.